Akkermansia, also known as Akk bacteria, is called Akkermansia muciniphila. Akkermann’s bacterium is just a common symbiotic bacterium living in intestinal mucosa, which metabolizes mucin as its food every day, and it is found in nearly 80% of the population, accounting for 0.5-5% of the human intestinal flora. Many animal experiments, even clinical trials, have been done on this bacterium since its isolation. At present, there is a negative correlation between Akkermann’s bacteria and several unhealthy physical conditions, such as obesity, diabetes, intestinal inflammation, liver disease or chronic drinking.

The decrease of Akkermann’s bacteria will destroy the intestinal barrier function, lead to the increase of plasma endotoxin level and eventually lead to low-grade inflammation and metabolic disorder.

Therefore, researchers have seen the potential of Akkermann’s bacteria as the next generation of probiotic drugs. It is expected to become a potential target of metabolic diseases such as obesity and diabetes, and fight diseases at the microbial level.